Can GLP‑1 drugs curb addiction?
Emerging evidence shows promise but important limits remain
Multiple recent studies suggest glucagon‑like peptide‑1 (GLP‑1) receptor agonists — drugs developed for diabetes and now widely used for weight loss — may reduce the risk of substance use disorders. Large observational analyses, including data drawn from Veterans Affairs health records, found that people who started GLP‑1 medications had a lower incidence of new substance‑use diagnoses and fewer overdoses compared with matched patients who did not start these drugs.
Researchers point to biological plausibility: GLP‑1 receptors are present in brain circuits that govern reward and craving. Animal experiments and early human research indicate these drugs can blunt the reinforcing effects of alcohol, opioids and stimulants, which may translate into reduced consumption or relapse in some people.
Key implications and caveats
- Potential benefits: GLP‑1s could offer a pharmacologic tool to complement behavioural treatments and existing medicines for addiction, expanding options for people who struggle with cravings.
- Evidence level: Most human data to date are observational or from early‑phase trials; causal benefits and long‑term efficacy remain unproven.
- Safety and access: GLP‑1s carry side‑effect profiles and new studies have raised concerns about bone health and gout risk. Widespread off‑label use without clear guidelines could create harms and equity issues.
What clinicians and policymakers should consider
- Prioritise rigorous clinical trials that test GLP‑1s specifically for substance‑use disorders across different substances.
- Monitor long‑term safety, interactions with addiction treatments, and which patient groups benefit most.
- Avoid substituting pharmacologic treatment for comprehensive care; behavioural support and social services remain central to recovery.
For now, the evidence is promising but preliminary. Large randomized trials will be needed to determine how these drugs should be used in addiction care.